OBJECTIVE: To investigate if loss of extracellular matrix metalloprotease inducer (EMMPRIN) will inhibit the growth of head and neck squamous cell carcinoma (HNSCC) tumor cell lines in vivo. Tumor cell-derived EMMPRIN is highly overexpressed in HNSCC and is thought to be induced by surrounding fibroblasts to stimulate matrix metalloproteases, which modulate tumor cell invasion, growth, and angiogenesis. DESIGN: In vivo study using FaDu tumor xenografts. SETTING: Academic research facility. SUBJECTS: Severe combined immunodeficiency (SCID) mice. INTERVENTIONS: The HNSCC cell line FaDu was transfected with EMMPRIN (FaDu/E), control vector (FaDu), or plasmid-expressing small-interfering RNA against EMMPRIN (FaDu/siE). Tumor cells combined with fibroblast cells were xenografted onto the flank of SCID mice. Tumors were measured biweekly over 4 weeks, at which time the mice were killed, and tumor samples were analyzed for proliferation (Ki-67 immunohistochemical analysis), vascularization (factor VIII staining), and apoptosis (TUNEL [terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling] assay). MAIN OUTCOME MEASURE: Growth of head and neck cancer cell lines genetically engineered to express variable levels of EMMPRIN. RESULTS: Tumor growth positively correlated and animal survival negatively correlated with increasing EMMPRIN expression. FaDu/E tumor growth was significantly larger at 4 weeks compared with FaDu tumors (P = .006). Similarly, the control vector-transfected FaDu tumors were significantly larger than FaDu/siE (P < .001). Immunohistochemical analysis demonstrated increased Ki-67 in EMMPRIN-transfected cells, without a significant change in the rate of apoptosis between groups. Vascular density and tumor formation rate also increased significantly with EMMPRIN expression. CONCLUSION: This study suggests that anti-EMMPRIN-targeted therapy may prove to be a novel treatment option in HNSCC.
OBJECTIVE: To investigate if loss of extracellular matrix metalloprotease inducer (EMMPRIN) will inhibit the growth of head and neck squamous cell carcinoma (HNSCC) tumor cell lines in vivo. Tumor cell-derived EMMPRIN is highly overexpressed in HNSCC and is thought to be induced by surrounding fibroblasts to stimulate matrix metalloproteases, which modulate tumor cell invasion, growth, and angiogenesis. DESIGN: In vivo study using FaDutumor xenografts. SETTING: Academic research facility. SUBJECTS: Severe combined immunodeficiency (SCID) mice. INTERVENTIONS: The HNSCC cell line FaDu was transfected with EMMPRIN (FaDu/E), control vector (FaDu), or plasmid-expressing small-interfering RNA against EMMPRIN (FaDu/siE). Tumor cells combined with fibroblast cells were xenografted onto the flank of SCIDmice. Tumors were measured biweekly over 4 weeks, at which time the mice were killed, and tumor samples were analyzed for proliferation (Ki-67 immunohistochemical analysis), vascularization (factor VIII staining), and apoptosis (TUNEL [terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling] assay). MAIN OUTCOME MEASURE: Growth of head and neck cancer cell lines genetically engineered to express variable levels of EMMPRIN. RESULTS:Tumor growth positively correlated and animal survival negatively correlated with increasing EMMPRIN expression. FaDu/E tumor growth was significantly larger at 4 weeks compared with FaDu tumors (P = .006). Similarly, the control vector-transfected FaDu tumors were significantly larger than FaDu/siE (P < .001). Immunohistochemical analysis demonstrated increased Ki-67 in EMMPRIN-transfected cells, without a significant change in the rate of apoptosis between groups. Vascular density and tumor formation rate also increased significantly with EMMPRIN expression. CONCLUSION: This study suggests that anti-EMMPRIN-targeted therapy may prove to be a novel treatment option in HNSCC.
Authors: Yi Tang; Marian T Nakada; Prabakaran Kesavan; Francis McCabe; Hillary Millar; Patricia Rafferty; Peter Bugelski; Li Yan Journal: Cancer Res Date: 2005-04-15 Impact factor: 12.701
Authors: Nadarajah Vigneswaran; Simone Beckers; Sabine Waigel; John Mensah; Jean Wu; Juan Mo; Kenneth E Fleisher; Jerry Bouquot; Peter G Sacks; Wolfgang Zacharias Journal: Exp Mol Pathol Date: 2005-11-28 Impact factor: 3.362
Authors: Eben L Rosenthal; Satya Shreenivas; Glenn E Peters; William E Grizzle; Renee Desmond; Candece L Gladson Journal: Laryngoscope Date: 2003-08 Impact factor: 3.325
Authors: Joseph A Knowles; Cara H Heath; Reshu Saini; Heidi Umphrey; Jason Warram; Kenneth Hoyt; Eben L Rosenthal Journal: Arch Otolaryngol Head Neck Surg Date: 2012-07
Authors: Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal Journal: Mol Cancer Res Date: 2011-06-10 Impact factor: 5.852
Authors: Nichole Renae Dean; Joseph A Knowles; Emily E Helman; Joszi C Aldridge; William R Carroll; Jeffery Scott Magnuson; Lisa Clemons; Barry Ziober; Eben L Rosenthal Journal: Anticancer Drugs Date: 2010-10 Impact factor: 2.248
Authors: Larissa Sweeny; Yolanda E Hartman; Kurt R Zinn; James R Prudent; David J Marshall; Mohammed S Shekhani; Eben L Rosenthal Journal: Oral Oncol Date: 2013-08-03 Impact factor: 5.337
Authors: Nichole R Dean; J Robert Newman; Emily E Helman; Wenyue Zhang; Seena Safavy; D M Weeks; Mark Cunningham; Linda A Snyder; Yi Tang; Li Yan; Lacey R McNally; Donald J Buchsbaum; Eben L Rosenthal Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531